Neuropathic Pain Market
Neuropathic Pain Market Study by Tricyclic Antidepressants, Anticonvulsants, SNRIs, Capsaicin Cream, Local Anesthesia, Opioids, Steroids, and Other Drugs from 2024 to 2034
Analysis of Neuropathic Pain Market Covering 30+ Countries Including Analysis of US, Canada, UK, Germany, France, Nordics, GCC countries, Japan, Korea and many more
Neuropathic Pain Market Outlook (2024 to 2034)
The neuropathic pain market size was around US$ 6,316.6 million in 2019. In 2024, the net worth of neuropathic drugs to be sold along with the nerve pain relief services is estimated to be around US$ 8,382.9 million. The global demand for neuropathic pain relief medications and services is poised to witness a CAGR of 5.7% through 2034. The industry is forecasted to reach a value of US$ 14,538.7 million by 2034.
The market is being propelled by the development of new mechanisms for nerve pain relief in neurological pain treatment. Neuropathic medications use these advancements to create novel, more effective medications that can fill the gaps in patient treatment procedures.
Don't Need a Global Report?
save 40%! on Country & Region specific reports
Neuropathic Pain Market Trends and Analysis
Localized pain treatment without systemic side effects has been made possible by advancements in topical neuropathy for pain relief. So, to produce topical remedies, market participants are investing in research and development, which has also broadened the spectrum of therapy alternatives.
Research on genomics and biomarkers in pain genetics has improved the knowledge and understanding of the processes behind neuropathic pain. By using this information, many pharmaceutical companies are also entering the sector to provide individualized and efficient pain management with novel medications.
| Report Attributes | Details |
|---|---|
| Estimated Market Value (2024E) | US$ 8,382.9 million |
| Forecasted Market Value (2034F) | US$ 14,538.7 million |
| Global Market Growth Rate (2024 to 2034) | 5.7% CAGR |
| Anticonvulsant Segment Growth Rate (2024 to 2034) | 6.4% CAGR |
| Chemotherapy-Induced Peripheral Neuropathy Segment Growth Rate (2024 to 2034) | 6% CAGR |
| Retail Pharmacies Segment Growth Rate (2024 to 2034) | 5.6% CAGR |
| North America Market Share (2024) | 39.3% |
| Western Europe Market Share (2024) | 28.2% |
| East Asia Market Share (2024) | 14.2% |
| Key Companies Profiled | Pfizer Inc.; Johnson & Johnson Services, Inc; Bristol-Myers Squibb Company; Sanofi S.A; GlaxoSmithKline plc; Eli Lilly and Company; Teva Pharmaceutical Industries Ltd; Baxter International Inc. |
What is the Major Factor Fueling Growth in the Neuropathic Pain Market?
“Personalized and Virtual Neuropathic Nerve Damage Treatment”
The use of personalized medicine techniques that allow painkillers to be customized to the unique needs of each patient is an emerging trend in the neuropathic pain management market. So, leading market players have started providing tailored treatments based on lifestyle, genetic, and environmental variables, consequently improving treatment results and patient satisfaction.
By incorporating digital health technologies into pain treatment, neuropathic patient monitoring and engagement services have improved manifold in the last few years. During the pandemic years, neuropathic pain management service providers introduced wearable technology, telemedicine, and smartphone apps to help patients better measure and manage their pain at home.
More Insights, Lesser Cost (-50% off)
Insights on import/export production,
pricing analysis, and more – Only @ Fact.MR
Country-wise Insights
| Country | CAGR (2024 to 2034) |
|---|---|
| United States | 13.6% |
| Germany | 6.2% |
| China | 7.5% |
What is Stimulating the United States Neuropathic Pain Market?
“Widespread Presence of Neuropathic Pain Support Groups in the United States”
The neuropathic pain industry in North America is valued at US$ 3,295 million in 2024. Different combination treatments are quite popular among patients in North America, and they also enable doctors to create drugs that target several pain circuits at once.
The neuropathic pain industries in the United States are expected to contribute to 78.1% of the North American market sales in 2024, making it the dominant country in the region. A sizable market for chronic pain relief drugs in the United States has been created by the growing percentage of the elderly population, who are more susceptible to neuropathic pain problems.
The growth of neuropathic pain solutions and products is likely to witness a CAGR of 13.6% through 2034. The healthcare sector’s emphasis on solving the complexities arising from the link between neuropathic pain and mental health is figured out to be the prime reason for market growth over the projected years. On the other hand, Canada is expected to witness a CAGR of 5.4% during this period.
Which is the Leading Market for Neuropathic Pain Relief Products in East Asia?
“China to Overtake Japan in Production of Neuropathic Pain Drugs”
The neuropathic pain market in East Asia is estimated to be worth around US$ 1,187 million in 2024. The market has grown in East Asian countries with the rising incidence of chronic nerve pain disorders such as diabetic neuropathy and post-herpetic neuralgia. Drug manufacturers in China, Japan, and South Korea are capitalizing on this expanding patient base by providing a range of medications for managing the symptoms of neuropathic pain.
The demand for neuropathic pain management medications and services in East Asia is likely to increase at 6.6% CAGR till 2034. The analysis also reveals that Japan, with a regional market share of 40.7% in 2024, is likely to be the leading market in East Asia. With a considerable share of the aged population, the demand for neuropathic pain diagnosis and management services in Japan is estimated to generate a revenue of around US$ 483 million in 2024.
On the other hand, the production and sales of neuropathic pain relief options in China are anticipated to grow at a faster rate than in Japan through the projected years. The China market is likely to expand at a CAGR of 7.5%, reaching a valuation of US$ 973 million by 2034.
Category-wise Insights
Which Type of Drug is Widely Used for Neuropathic Pain Recovery?
“Wide Use of Anticonvulsant Neuropathic Pain Relief Medication to Continue”
| Attribute | Details |
|---|---|
| Market Share in 2024 | 42.6% |
Among the different types or classes of drugs used for neuropathic pain relief, anticonvulsants constitute the leading drug segment, with an overall market share of 42.6% in 2024. Non-opioid alternatives for neuropathic pain management are receiving more attention due to rising concerns about opioid abuse.
So, in line with this trend toward safer and longer-lasting pain management solutions, market players are supplying novel anticonvulsant painkillers. Through the projected years, the global demand for anticonvulsants is projected to rise at a CAGR of 6.4%, and the net worth of this segment is expected to reach US$ 6,666.4 million by 2034.
Tricyclic anti-depressant pharmaceuticals with age-appropriate dosages and formulations according to the specific needs of patients in different age groups constitute the second leading segment. The segment is poised to offer more opportunities for new market players by expanding at a CAGR of 5.8% from 2024 to 2034. The net revenue generated by this segment is expected to be around US$ 5,140.8 million by 2034, growing from US$ 2,928.6 million in 2024.
Which is the Leading Indication Segment in the Neuropathic Pain Market?
“Higher Demand Diabetic Neuropathy Treatment Solutions”
| Attribute | Details |
|---|---|
| Market Share in 2024 | 45.8% |
Based on the indication, the diabetic neuropathy segment is expected to contribute 45.8% of the total market share in 2024. The segment is poised to follow a growth rate of 5.6% over the next ten years. The segment is expected to create a business opportunity of US$ 6,439.7 million by 2034, increasing from US$ 3,837 million in 2024.
The development and implementation of chemotherapy-induced peripheral neuropathy solutions have strengthened through collaborations with pain experts and multidisciplinary care teams.
Neuropathic pain drug suppliers who work closely with such medical experts to guarantee complete and patient-focused pain treatment plans are expected to gain higher profits from this segment. This segment is anticipated to witness a CAGR of 6% over the forecast period and reach a valuation of 6,630.6 million by 2034.
Know thy Competitors
Competitive landscape highlights only certain players
Complete list available upon request
Competitive Landscape
Key players in the neuropathic pain market include Pfizer Inc., Johnson & Johnson Services, Inc., Bristol-Myers Squibb Company, Sanofi S.A, GlaxoSmithKline plc, Eli Lilly and Company, Teva Pharmaceutical Industries Ltd., and Baxter International Inc.
The legitimacy and accessibility of neuropathic pain drugs developed and improved through partnerships of leading players with healthcare organizations. Besides their strict adherence to health regulations, they are rewarded with a greater market share. However, programs run by the government that deal with managing chronic pain have supported the emergence of many neuropathic pain remedy suppliers recently.
Recent Developments
- In September 2022, a phase 2 clinical trial was started by AlgoTx Corporation to assess ATX01 for people who have chemotherapy-induced peripheral neuropathy (CIPN). For this innovative medication, topical amitriptyline, the company carried out the clinical trial in more than 40 locations across Europe and the United States.
- In January 2020, scientists at Huazhong Agricultural University in China established that neuropathic pain can be prevented by Synaptotagmin 1 (Syt-1), which is a synaptic vesicle protein. Researchers claim that it controls the exocytosis of neurotransmitters and neuropathic pain is alleviated by electroacupuncture by suppressing spinal Syt-1. Numerous other studies have also revealed that neuropathic pain can be effectively managed by using electroacupuncture methods.
Key Segments Covered by Neuropathic Pain Industry Survey Report
-
By Drug Class :
- Tricyclic Anti-Depressants
- Anticonvulsants
- SNRI's
- Capsaicin Cream
- Local Anesthesia
- Opioids
- Steroids
- Other Drugs
-
By Indication Type :
- Diabetic Neuropathy
- Trigeminal Neuralgia
- Post-Herpetic Neuralgia
- Chemotherapy-Induced Peripheral Neuropathy
- Other Indications
-
By Sales/Distribution Channel :
- Retail Pharmacies
- Hospital Pharmacies
- Online Pharmacies
- Other Sales Channels
-
By Region :
- North America Market
- Europe Market
- Latin America Market
- East Asia Market
- South Asia & Oceania Market
- Middle East & Africa (MEA) Market
Table of Content
- 1. Executive Summary
- 2. Market Overview
- 3. Market Background
- 4. Global Market Analysis 2019 to 2023 and Forecast, 2024 to 2034
- 5. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Drug Class
- 5.1. Tricyclic Anti-Depressant
- 5.2. Anticonvulsant
- 5.3. Local Anaesthesia
- 5.4. Opioids
- 5.5. Steroids
- 5.6. Others
- 6. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Indication
- 6.1. Diabetic Neuropathy
- 6.2. Chemotherapy-induced Peripheral Neuropathy
- 6.3. Other
- 7. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Distribution Channel
- 7.1. Retail Pharmacies
- 7.2. Drug Store
- 7.3. Online Pharmacies
- 8. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Region
- 8.1. North America
- 8.2. Latin America
- 8.3. Western Europe
- 8.4. Eastern Europe
- 8.5. South Asia and Pacific
- 8.6. East Asia
- 8.7. Middle East and Africa
- 9. North America Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country
- 10. Latin America Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country
- 11. Western Europe Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country
- 12. Eastern Europe Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country
- 13. South Asia and Pacific Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country
- 14. East Asia Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country
- 15. Middle East and Africa Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country
- 16. Key Countries Market Analysis
- 17. Market Structure Analysis
- 18. Competition Analysis
- 18.1. Pfizer, Inc
- 18.2. Johnson & Johnson Services, Inc
- 18.3. Sanofi S.A
- 18.4. Eily Lily and Company
- 18.5. GlaxoSmithKline PLC
- 18.6. Biogen Idec
- 18.7. Bristol-Myers Squibb
- 18.8. Baxter Healthcare Corporation
- 18.9. Depomed, Inc.
- 19. Assumptions & Acronyms Used
- 20. Research Methodology
Don't Need a Global Report?
save 40%! on Country & Region specific reports
List Of Table
Table 1: Global Market Value (US$ Mn) Forecast by Region, 2019 to 2034
Table 2: Global Market Volume (Units Pack) Forecast by Region, 2019 to 2034
Table 3: Global Market Value (US$ Mn) Forecast by Drug Class, 2019 to 2034
Table 4: Global Market Volume (Units Pack) Forecast by Drug Class, 2019 to 2034
Table 5: Global Market Value (US$ Mn) Forecast by Indication, 2019 to 2034
Table 6: Global Market Volume (Units Pack) Forecast by Indication, 2019 to 2034
Table 7: Global Market Value (US$ Mn) Forecast by Distribution Channel, 2019 to 2034
Table 8: Global Market Volume (Units Pack) Forecast by Distribution Channel, 2019 to 2034
Table 9: North America Market Value (US$ Mn) Forecast by Country, 2019 to 2034
Table 10: North America Market Volume (Units Pack) Forecast by Country, 2019 to 2034
Table 11: North America Market Value (US$ Mn) Forecast by Drug Class, 2019 to 2034
Table 12: North America Market Volume (Units Pack) Forecast by Drug Class, 2019 to 2034
Table 13: North America Market Value (US$ Mn) Forecast by Indication, 2019 to 2034
Table 14: North America Market Volume (Units Pack) Forecast by Indication, 2019 to 2034
Table 15: North America Market Value (US$ Mn) Forecast by Distribution Channel, 2019 to 2034
Table 16: North America Market Volume (Units Pack) Forecast by Distribution Channel, 2019 to 2034
Table 17: Latin America Market Value (US$ Mn) Forecast by Country, 2019 to 2034
Table 18: Latin America Market Volume (Units Pack) Forecast by Country, 2019 to 2034
Table 19: Latin America Market Value (US$ Mn) Forecast by Drug Class, 2019 to 2034
Table 20: Latin America Market Volume (Units Pack) Forecast by Drug Class, 2019 to 2034
Table 21: Latin America Market Value (US$ Mn) Forecast by Indication, 2019 to 2034
Table 22: Latin America Market Volume (Units Pack) Forecast by Indication, 2019 to 2034
Table 23: Latin America Market Value (US$ Mn) Forecast by Distribution Channel, 2019 to 2034
Table 24: Latin America Market Volume (Units Pack) Forecast by Distribution Channel, 2019 to 2034
Table 25: Western Europe Market Value (US$ Mn) Forecast by Country, 2019 to 2034
Table 26: Western Europe Market Volume (Units Pack) Forecast by Country, 2019 to 2034
Table 27: Western Europe Market Value (US$ Mn) Forecast by Drug Class, 2019 to 2034
Table 28: Western Europe Market Volume (Units Pack) Forecast by Drug Class, 2019 to 2034
Table 29: Western Europe Market Value (US$ Mn) Forecast by Indication, 2019 to 2034
Table 30: Western Europe Market Volume (Units Pack) Forecast by Indication, 2019 to 2034
Table 31: Western Europe Market Value (US$ Mn) Forecast by Distribution Channel, 2019 to 2034
Table 32: Western Europe Market Volume (Units Pack) Forecast by Distribution Channel, 2019 to 2034
Table 33: Eastern Europe Market Value (US$ Mn) Forecast by Country, 2019 to 2034
Table 34: Eastern Europe Market Volume (Units Pack) Forecast by Country, 2019 to 2034
Table 35: Eastern Europe Market Value (US$ Mn) Forecast by Drug Class, 2019 to 2034
Table 36: Eastern Europe Market Volume (Units Pack) Forecast by Drug Class, 2019 to 2034
Table 37: Eastern Europe Market Value (US$ Mn) Forecast by Indication, 2019 to 2034
Table 38: Eastern Europe Market Volume (Units Pack) Forecast by Indication, 2019 to 2034
Table 39: Eastern Europe Market Value (US$ Mn) Forecast by Distribution Channel, 2019 to 2034
Table 40: Eastern Europe Market Volume (Units Pack) Forecast by Distribution Channel, 2019 to 2034
Table 41: South Asia and Pacific Market Value (US$ Mn) Forecast by Country, 2019 to 2034
Table 42: South Asia and Pacific Market Volume (Units Pack) Forecast by Country, 2019 to 2034
Table 43: South Asia and Pacific Market Value (US$ Mn) Forecast by Drug Class, 2019 to 2034
Table 44: South Asia and Pacific Market Volume (Units Pack) Forecast by Drug Class, 2019 to 2034
Table 45: South Asia and Pacific Market Value (US$ Mn) Forecast by Indication, 2019 to 2034
Table 46: South Asia and Pacific Market Volume (Units Pack) Forecast by Indication, 2019 to 2034
Table 47: South Asia and Pacific Market Value (US$ Mn) Forecast by Distribution Channel, 2019 to 2034
Table 48: South Asia and Pacific Market Volume (Units Pack) Forecast by Distribution Channel, 2019 to 2034
Table 49: East Asia Market Value (US$ Mn) Forecast by Country, 2019 to 2034
Table 50: East Asia Market Volume (Units Pack) Forecast by Country, 2019 to 2034
Table 51: East Asia Market Value (US$ Mn) Forecast by Drug Class, 2019 to 2034
Table 52: East Asia Market Volume (Units Pack) Forecast by Drug Class, 2019 to 2034
Table 53: East Asia Market Value (US$ Mn) Forecast by Indication, 2019 to 2034
Table 54: East Asia Market Volume (Units Pack) Forecast by Indication, 2019 to 2034
Table 55: East Asia Market Value (US$ Mn) Forecast by Distribution Channel, 2019 to 2034
Table 56: East Asia Market Volume (Units Pack) Forecast by Distribution Channel, 2019 to 2034
Table 57: Middle East and Africa Market Value (US$ Mn) Forecast by Country, 2019 to 2034
Table 58: Middle East and Africa Market Volume (Units Pack) Forecast by Country, 2019 to 2034
Table 59: Middle East and Africa Market Value (US$ Mn) Forecast by Drug Class, 2019 to 2034
Table 60: Middle East and Africa Market Volume (Units Pack) Forecast by Drug Class, 2019 to 2034
Table 61: Middle East and Africa Market Value (US$ Mn) Forecast by Indication, 2019 to 2034
Table 62: Middle East and Africa Market Volume (Units Pack) Forecast by Indication, 2019 to 2034
Table 63: Middle East and Africa Market Value (US$ Mn) Forecast by Distribution Channel, 2019 to 2034
Table 64: Middle East and Africa Market Volume (Units Pack) Forecast by Distribution Channel, 2019 to 2034
More Insights, Lesser Cost (-50% off)
Insights on import/export production,
pricing analysis, and more – Only @ Fact.MR
List Of Figures
Figure 1: Global Market Value (US$ Mn) by Drug Class, 2024 to 2034
Figure 2: Global Market Value (US$ Mn) by Indication, 2024 to 2034
Figure 3: Global Market Value (US$ Mn) by Distribution Channel, 2024 to 2034
Figure 4: Global Market Value (US$ Mn) by Region, 2024 to 2034
Figure 5: Global Market Value (US$ Mn) Analysis by Region, 2019 to 2034
Figure 6: Global Market Volume (Units Pack) Analysis by Region, 2019 to 2034
Figure 7: Global Market Value Share (%) and BPS Analysis by Region, 2024 to 2034
Figure 8: Global Market Y-o-Y Growth (%) Projections by Region, 2024 to 2034
Figure 9: Global Market Value (US$ Mn) Analysis by Drug Class, 2019 to 2034
Figure 10: Global Market Volume (Units Pack) Analysis by Drug Class, 2019 to 2034
Figure 11: Global Market Value Share (%) and BPS Analysis by Drug Class, 2024 to 2034
Figure 12: Global Market Y-o-Y Growth (%) Projections by Drug Class, 2024 to 2034
Figure 13: Global Market Value (US$ Mn) Analysis by Indication, 2019 to 2034
Figure 14: Global Market Volume (Units Pack) Analysis by Indication, 2019 to 2034
Figure 15: Global Market Value Share (%) and BPS Analysis by Indication, 2024 to 2034
Figure 16: Global Market Y-o-Y Growth (%) Projections by Indication, 2024 to 2034
Figure 17: Global Market Value (US$ Mn) Analysis by Distribution Channel, 2019 to 2034
Figure 18: Global Market Volume (Units Pack) Analysis by Distribution Channel, 2019 to 2034
Figure 19: Global Market Value Share (%) and BPS Analysis by Distribution Channel, 2024 to 2034
Figure 20: Global Market Y-o-Y Growth (%) Projections by Distribution Channel, 2024 to 2034
Figure 21: Global Market Attractiveness by Drug Class, 2024 to 2034
Figure 22: Global Market Attractiveness by Indication, 2024 to 2034
Figure 23: Global Market Attractiveness by Distribution Channel, 2024 to 2034
Figure 24: Global Market Attractiveness by Region, 2024 to 2034
Figure 25: North America Market Value (US$ Mn) by Drug Class, 2024 to 2034
Figure 26: North America Market Value (US$ Mn) by Indication, 2024 to 2034
Figure 27: North America Market Value (US$ Mn) by Distribution Channel, 2024 to 2034
Figure 28: North America Market Value (US$ Mn) by Country, 2024 to 2034
Figure 29: North America Market Value (US$ Mn) Analysis by Country, 2019 to 2034
Figure 30: North America Market Volume (Units Pack) Analysis by Country, 2019 to 2034
Figure 31: North America Market Value Share (%) and BPS Analysis by Country, 2024 to 2034
Figure 32: North America Market Y-o-Y Growth (%) Projections by Country, 2024 to 2034
Figure 33: North America Market Value (US$ Mn) Analysis by Drug Class, 2019 to 2034
Figure 34: North America Market Volume (Units Pack) Analysis by Drug Class, 2019 to 2034
Figure 35: North America Market Value Share (%) and BPS Analysis by Drug Class, 2024 to 2034
Figure 36: North America Market Y-o-Y Growth (%) Projections by Drug Class, 2024 to 2034
Figure 37: North America Market Value (US$ Mn) Analysis by Indication, 2019 to 2034
Figure 38: North America Market Volume (Units Pack) Analysis by Indication, 2019 to 2034
Figure 39: North America Market Value Share (%) and BPS Analysis by Indication, 2024 to 2034
Figure 40: North America Market Y-o-Y Growth (%) Projections by Indication, 2024 to 2034
Figure 41: North America Market Value (US$ Mn) Analysis by Distribution Channel, 2019 to 2034
Figure 42: North America Market Volume (Units Pack) Analysis by Distribution Channel, 2019 to 2034
Figure 43: North America Market Value Share (%) and BPS Analysis by Distribution Channel, 2024 to 2034
Figure 44: North America Market Y-o-Y Growth (%) Projections by Distribution Channel, 2024 to 2034
Figure 45: North America Market Attractiveness by Drug Class, 2024 to 2034
Figure 46: North America Market Attractiveness by Indication, 2024 to 2034
Figure 47: North America Market Attractiveness by Distribution Channel, 2024 to 2034
Figure 48: North America Market Attractiveness by Country, 2024 to 2034
Figure 49: Latin America Market Value (US$ Mn) by Drug Class, 2024 to 2034
Figure 50: Latin America Market Value (US$ Mn) by Indication, 2024 to 2034
Figure 51: Latin America Market Value (US$ Mn) by Distribution Channel, 2024 to 2034
Figure 52: Latin America Market Value (US$ Mn) by Country, 2024 to 2034
Figure 53: Latin America Market Value (US$ Mn) Analysis by Country, 2019 to 2034
Figure 54: Latin America Market Volume (Units Pack) Analysis by Country, 2019 to 2034
Figure 55: Latin America Market Value Share (%) and BPS Analysis by Country, 2024 to 2034
Figure 56: Latin America Market Y-o-Y Growth (%) Projections by Country, 2024 to 2034
Figure 57: Latin America Market Value (US$ Mn) Analysis by Drug Class, 2019 to 2034
Figure 58: Latin America Market Volume (Units Pack) Analysis by Drug Class, 2019 to 2034
Figure 59: Latin America Market Value Share (%) and BPS Analysis by Drug Class, 2024 to 2034
Figure 60: Latin America Market Y-o-Y Growth (%) Projections by Drug Class, 2024 to 2034
Figure 61: Latin America Market Value (US$ Mn) Analysis by Indication, 2019 to 2034
Figure 62: Latin America Market Volume (Units Pack) Analysis by Indication, 2019 to 2034
Figure 63: Latin America Market Value Share (%) and BPS Analysis by Indication, 2024 to 2034
Figure 64: Latin America Market Y-o-Y Growth (%) Projections by Indication, 2024 to 2034
Figure 65: Latin America Market Value (US$ Mn) Analysis by Distribution Channel, 2019 to 2034
Figure 66: Latin America Market Volume (Units Pack) Analysis by Distribution Channel, 2019 to 2034
Figure 67: Latin America Market Value Share (%) and BPS Analysis by Distribution Channel, 2024 to 2034
Figure 68: Latin America Market Y-o-Y Growth (%) Projections by Distribution Channel, 2024 to 2034
Figure 69: Latin America Market Attractiveness by Drug Class, 2024 to 2034
Figure 70: Latin America Market Attractiveness by Indication, 2024 to 2034
Figure 71: Latin America Market Attractiveness by Distribution Channel, 2024 to 2034
Figure 72: Latin America Market Attractiveness by Country, 2024 to 2034
Figure 73: Western Europe Market Value (US$ Mn) by Drug Class, 2024 to 2034
Figure 74: Western Europe Market Value (US$ Mn) by Indication, 2024 to 2034
Figure 75: Western Europe Market Value (US$ Mn) by Distribution Channel, 2024 to 2034
Figure 76: Western Europe Market Value (US$ Mn) by Country, 2024 to 2034
Figure 77: Western Europe Market Value (US$ Mn) Analysis by Country, 2019 to 2034
Figure 78: Western Europe Market Volume (Units Pack) Analysis by Country, 2019 to 2034
Figure 79: Western Europe Market Value Share (%) and BPS Analysis by Country, 2024 to 2034
Figure 80: Western Europe Market Y-o-Y Growth (%) Projections by Country, 2024 to 2034
Figure 81: Western Europe Market Value (US$ Mn) Analysis by Drug Class, 2019 to 2034
Figure 82: Western Europe Market Volume (Units Pack) Analysis by Drug Class, 2019 to 2034
Figure 83: Western Europe Market Value Share (%) and BPS Analysis by Drug Class, 2024 to 2034
Figure 84: Western Europe Market Y-o-Y Growth (%) Projections by Drug Class, 2024 to 2034
Figure 85: Western Europe Market Value (US$ Mn) Analysis by Indication, 2019 to 2034
Figure 86: Western Europe Market Volume (Units Pack) Analysis by Indication, 2019 to 2034
Figure 87: Western Europe Market Value Share (%) and BPS Analysis by Indication, 2024 to 2034
Figure 88: Western Europe Market Y-o-Y Growth (%) Projections by Indication, 2024 to 2034
Figure 89: Western Europe Market Value (US$ Mn) Analysis by Distribution Channel, 2019 to 2034
Figure 90: Western Europe Market Volume (Units Pack) Analysis by Distribution Channel, 2019 to 2034
Figure 91: Western Europe Market Value Share (%) and BPS Analysis by Distribution Channel, 2024 to 2034
Figure 92: Western Europe Market Y-o-Y Growth (%) Projections by Distribution Channel, 2024 to 2034
Figure 93: Western Europe Market Attractiveness by Drug Class, 2024 to 2034
Figure 94: Western Europe Market Attractiveness by Indication, 2024 to 2034
Figure 95: Western Europe Market Attractiveness by Distribution Channel, 2024 to 2034
Figure 96: Western Europe Market Attractiveness by Country, 2024 to 2034
Figure 97: Eastern Europe Market Value (US$ Mn) by Drug Class, 2024 to 2034
Figure 98: Eastern Europe Market Value (US$ Mn) by Indication, 2024 to 2034
Figure 99: Eastern Europe Market Value (US$ Mn) by Distribution Channel, 2024 to 2034
Figure 100: Eastern Europe Market Value (US$ Mn) by Country, 2024 to 2034
Figure 101: Eastern Europe Market Value (US$ Mn) Analysis by Country, 2019 to 2034
Figure 102: Eastern Europe Market Volume (Units Pack) Analysis by Country, 2019 to 2034
Figure 103: Eastern Europe Market Value Share (%) and BPS Analysis by Country, 2024 to 2034
Figure 104: Eastern Europe Market Y-o-Y Growth (%) Projections by Country, 2024 to 2034
Figure 105: Eastern Europe Market Value (US$ Mn) Analysis by Drug Class, 2019 to 2034
Figure 106: Eastern Europe Market Volume (Units Pack) Analysis by Drug Class, 2019 to 2034
Figure 107: Eastern Europe Market Value Share (%) and BPS Analysis by Drug Class, 2024 to 2034
Figure 108: Eastern Europe Market Y-o-Y Growth (%) Projections by Drug Class, 2024 to 2034
Figure 109: Eastern Europe Market Value (US$ Mn) Analysis by Indication, 2019 to 2034
Figure 110: Eastern Europe Market Volume (Units Pack) Analysis by Indication, 2019 to 2034
Figure 111: Eastern Europe Market Value Share (%) and BPS Analysis by Indication, 2024 to 2034
Figure 112: Eastern Europe Market Y-o-Y Growth (%) Projections by Indication, 2024 to 2034
Figure 113: Eastern Europe Market Value (US$ Mn) Analysis by Distribution Channel, 2019 to 2034
Figure 114: Eastern Europe Market Volume (Units Pack) Analysis by Distribution Channel, 2019 to 2034
Figure 115: Eastern Europe Market Value Share (%) and BPS Analysis by Distribution Channel, 2024 to 2034
Figure 116: Eastern Europe Market Y-o-Y Growth (%) Projections by Distribution Channel, 2024 to 2034
Figure 117: Eastern Europe Market Attractiveness by Drug Class, 2024 to 2034
Figure 118: Eastern Europe Market Attractiveness by Indication, 2024 to 2034
Figure 119: Eastern Europe Market Attractiveness by Distribution Channel, 2024 to 2034
Figure 120: Eastern Europe Market Attractiveness by Country, 2024 to 2034
Figure 121: South Asia and Pacific Market Value (US$ Mn) by Drug Class, 2024 to 2034
Figure 122: South Asia and Pacific Market Value (US$ Mn) by Indication, 2024 to 2034
Figure 123: South Asia and Pacific Market Value (US$ Mn) by Distribution Channel, 2024 to 2034
Figure 124: South Asia and Pacific Market Value (US$ Mn) by Country, 2024 to 2034
Figure 125: South Asia and Pacific Market Value (US$ Mn) Analysis by Country, 2019 to 2034
Figure 126: South Asia and Pacific Market Volume (Units Pack) Analysis by Country, 2019 to 2034
Figure 127: South Asia and Pacific Market Value Share (%) and BPS Analysis by Country, 2024 to 2034
Figure 128: South Asia and Pacific Market Y-o-Y Growth (%) Projections by Country, 2024 to 2034
Figure 129: South Asia and Pacific Market Value (US$ Mn) Analysis by Drug Class, 2019 to 2034
Figure 130: South Asia and Pacific Market Volume (Units Pack) Analysis by Drug Class, 2019 to 2034
Figure 131: South Asia and Pacific Market Value Share (%) and BPS Analysis by Drug Class, 2024 to 2034
Figure 132: South Asia and Pacific Market Y-o-Y Growth (%) Projections by Drug Class, 2024 to 2034
Figure 133: South Asia and Pacific Market Value (US$ Mn) Analysis by Indication, 2019 to 2034
Figure 134: South Asia and Pacific Market Volume (Units Pack) Analysis by Indication, 2019 to 2034
Figure 135: South Asia and Pacific Market Value Share (%) and BPS Analysis by Indication, 2024 to 2034
Figure 136: South Asia and Pacific Market Y-o-Y Growth (%) Projections by Indication, 2024 to 2034
Figure 137: South Asia and Pacific Market Value (US$ Mn) Analysis by Distribution Channel, 2019 to 2034
Figure 138: South Asia and Pacific Market Volume (Units Pack) Analysis by Distribution Channel, 2019 to 2034
Figure 139: South Asia and Pacific Market Value Share (%) and BPS Analysis by Distribution Channel, 2024 to 2034
Figure 140: South Asia and Pacific Market Y-o-Y Growth (%) Projections by Distribution Channel, 2024 to 2034
Figure 141: South Asia and Pacific Market Attractiveness by Drug Class, 2024 to 2034
Figure 142: South Asia and Pacific Market Attractiveness by Indication, 2024 to 2034
Figure 143: South Asia and Pacific Market Attractiveness by Distribution Channel, 2024 to 2034
Figure 144: South Asia and Pacific Market Attractiveness by Country, 2024 to 2034
Figure 145: East Asia Market Value (US$ Mn) by Drug Class, 2024 to 2034
Figure 146: East Asia Market Value (US$ Mn) by Indication, 2024 to 2034
Figure 147: East Asia Market Value (US$ Mn) by Distribution Channel, 2024 to 2034
Figure 148: East Asia Market Value (US$ Mn) by Country, 2024 to 2034
Figure 149: East Asia Market Value (US$ Mn) Analysis by Country, 2019 to 2034
Figure 150: East Asia Market Volume (Units Pack) Analysis by Country, 2019 to 2034
Figure 151: East Asia Market Value Share (%) and BPS Analysis by Country, 2024 to 2034
Figure 152: East Asia Market Y-o-Y Growth (%) Projections by Country, 2024 to 2034
Figure 153: East Asia Market Value (US$ Mn) Analysis by Drug Class, 2019 to 2034
Figure 154: East Asia Market Volume (Units Pack) Analysis by Drug Class, 2019 to 2034
Figure 155: East Asia Market Value Share (%) and BPS Analysis by Drug Class, 2024 to 2034
Figure 156: East Asia Market Y-o-Y Growth (%) Projections by Drug Class, 2024 to 2034
Figure 157: East Asia Market Value (US$ Mn) Analysis by Indication, 2019 to 2034
Figure 158: East Asia Market Volume (Units Pack) Analysis by Indication, 2019 to 2034
Figure 159: East Asia Market Value Share (%) and BPS Analysis by Indication, 2024 to 2034
Figure 160: East Asia Market Y-o-Y Growth (%) Projections by Indication, 2024 to 2034
Figure 161: East Asia Market Value (US$ Mn) Analysis by Distribution Channel, 2019 to 2034
Figure 162: East Asia Market Volume (Units Pack) Analysis by Distribution Channel, 2019 to 2034
Figure 163: East Asia Market Value Share (%) and BPS Analysis by Distribution Channel, 2024 to 2034
Figure 164: East Asia Market Y-o-Y Growth (%) Projections by Distribution Channel, 2024 to 2034
Figure 165: East Asia Market Attractiveness by Drug Class, 2024 to 2034
Figure 166: East Asia Market Attractiveness by Indication, 2024 to 2034
Figure 167: East Asia Market Attractiveness by Distribution Channel, 2024 to 2034
Figure 168: East Asia Market Attractiveness by Country, 2024 to 2034
Figure 169: Middle East and Africa Market Value (US$ Mn) by Drug Class, 2024 to 2034
Figure 170: Middle East and Africa Market Value (US$ Mn) by Indication, 2024 to 2034
Figure 171: Middle East and Africa Market Value (US$ Mn) by Distribution Channel, 2024 to 2034
Figure 172: Middle East and Africa Market Value (US$ Mn) by Country, 2024 to 2034
Figure 173: Middle East and Africa Market Value (US$ Mn) Analysis by Country, 2019 to 2034
Figure 174: Middle East and Africa Market Volume (Units Pack) Analysis by Country, 2019 to 2034
Figure 175: Middle East and Africa Market Value Share (%) and BPS Analysis by Country, 2024 to 2034
Figure 176: Middle East and Africa Market Y-o-Y Growth (%) Projections by Country, 2024 to 2034
Figure 177: Middle East and Africa Market Value (US$ Mn) Analysis by Drug Class, 2019 to 2034
Figure 178: Middle East and Africa Market Volume (Units Pack) Analysis by Drug Class, 2019 to 2034
Figure 179: Middle East and Africa Market Value Share (%) and BPS Analysis by Drug Class, 2024 to 2034
Figure 180: Middle East and Africa Market Y-o-Y Growth (%) Projections by Drug Class, 2024 to 2034
Figure 181: Middle East and Africa Market Value (US$ Mn) Analysis by Indication, 2019 to 2034
Figure 182: Middle East and Africa Market Volume (Units Pack) Analysis by Indication, 2019 to 2034
Figure 183: Middle East and Africa Market Value Share (%) and BPS Analysis by Indication, 2024 to 2034
Figure 184: Middle East and Africa Market Y-o-Y Growth (%) Projections by Indication, 2024 to 2034
Figure 185: Middle East and Africa Market Value (US$ Mn) Analysis by Distribution Channel, 2019 to 2034
Figure 186: Middle East and Africa Market Volume (Units Pack) Analysis by Distribution Channel, 2019 to 2034
Figure 187: Middle East and Africa Market Value Share (%) and BPS Analysis by Distribution Channel, 2024 to 2034
Figure 188: Middle East and Africa Market Y-o-Y Growth (%) Projections by Distribution Channel, 2024 to 2034
Figure 189: Middle East and Africa Market Attractiveness by Drug Class, 2024 to 2034
Figure 190: Middle East and Africa Market Attractiveness by Indication, 2024 to 2034
Figure 191: Middle East and Africa Market Attractiveness by Distribution Channel, 2024 to 2034
Figure 192: Middle East and Africa Market Attractiveness by Country, 2024 to 2034
Know thy Competitors
Competitive landscape highlights only certain players
Complete list available upon request
- FAQs -
What was the Value of the Neuropathic Pain Market in 2019?
The neuropathic pain market was worth US$ 6,316.6 million in 2019.
What is the Sales Outlook for the Neuropathic Pain Medications in 2024?
The market is likely to be valued at US$ 8,382.9 million in 2024.
What is the Demand Forecast in the Market by 2034?
The market is expected to reach a valuation of US$ 14,538.7 million by 2034.
What is the Predicted Growth Rate of the Neuropathic Pain Market?
The adoption of medications to manage neuropathic pain is projected to rise at a CAGR of 5.7% through 2034.
At What Rate is the United States Neuropathic Pain Market Predicted to Grow?
The United States market is likely to register a CAGR of 13.6% through 2034.
Neuropathic Pain Market